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Objectives. Our aim was to determine the time saved by
administration of thrombolytic therapy at home rather than in the
hospital and to assess whether earlier thrombolysis resulted in
decreased mostly from acute myocardial infarction,
Background. There is much theoretic, experimental and trial
evidence to indicate that in acute myocardial infarction the earlier
that thrombolytic therapy is given, the greater its efficacy. How-
ever, the clinical importance of this time effect is uncertain .
Methods. In a randomized double-blind paralliel-group clinical
trial, 311 patients with suspected acute myocardial infarction seen
by their general practitioners within 4 h of symptom onset were
given intravenous anistreplase (30 U) either at home or later, after
arrival in the hospital .
Results. Anistreplase was given at home or in the hospital at
Theory suggests that the earlier thrombolytic therapy is
given after myocardial infarction, the more effective it
should be . Soon after a coronary thrombosis there is less
blood clot, with fewer fibrin cross-links, making lysis of the
thrombus easier than at a later stage . There is also a shorter
period of ischemia, so there will be less exterisive myocar-
dial necrosis if reperfusion is established . Theory is sup-
ported by the results of experimental coronary occlusion, in
which infarct size, mortality and residual dysfunction are
related to the time to reperfusion (1-4) .
However, evidence from clinical trials of greater efficacy
of thrombolytic therapy with earlier administration is equiv-
ocal, being apparent in the Gruppo Italiano per to Studio
della Streptochinasi nell'Infarto Miocardico trial (5) and the
Second International Study of Infarct Survival (6) but not in
the APSAC Intervention Mortality Study (7) or the Anglo-
Scandinavian Study of Early Thrombosis (8) . In the trials
that do demonstrate the "time effect --the increase in
efficacy of thrombolytic therapy with earlier administra-
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median times of 101 and 240 min, respectively, after symptom
onset. The median time saved by domiciliary thrombolysis was
130 min . Ey the end d I year after trial entry, 17 (10 .4%) of 163
patients given anistreplase at home died compared with 32
(21.6%) of 148 in those allotted anistreplase in the hospital
(relative reduction 52%, 95% confidence interval 14% to 89%,
p = I=
Conclusions. In this trial the time saved by domiciliary throni-
botysis by primary care physicians was >2 h . It is likely that a
similar time saving would be achieved if prehospital thrombolysis
were to become established practice. Pre hospital throtubolysis
resulted in a halving of the mortality rate from acute myocardial
infarction,
(J Ain Call Cardio! !994,23 :1-5)
tion-it is not pronounced . It has been estimated that a
decrease in the median time to treatment from 5 to 4 h would
improve the relative reduction of mortality fron , 20% to 23%,
an absolute mortality reduction of 0 .36%,% of time saved (6) .
However, the placebo-controlled trial on which this estimate
was based was not designed to demonstrate the time effect
and has an inherent bias against showing it because patients
with more severe infarction tend to present earlier (9-12) .
Thus, when thrombolytic therapy is given at the first oppor-
tunity, the outcome is the result of two opposing influences :
1) the greater efficacy of thrombolytic therapy with earlier
administration, and 2) the greater severity of infarction with
earlier presentation . The magnitude of the time effect can be
shown only by trials with a design in which patients are
randomly allocated to receive treatment immediately on
presentation or after a deliberate delay .
However, belief in the importance of the time effect is so
strong that it would now be considered unethical to conduct
a trial in the hospital to measure the magnitude of this effect .
Such a trial can be justified only if the late treatment group
were to receive thrombolytic therapy no later than usual and
the early treatment group were to receive treatment earlier
than usual, before admission to the hospital .
Substantial delays between patients' arrival in the hospi-
tal and their receiving thrombolytic therapy have been
reported on both sides of the Atlantic (13,14), and delays
I h are the rule rather than the exception
. A secondary aim
of a trial to assess the magnitude of the time effect should be
to determine the time saved by prehospital thrombolysis in
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practice . This creates a methodologic problem because the
conduct of the trial will focus attention on the hospital delay,
which is then reduced . The result will be an unrealistically
short time saving that will make it more difficult to demon-
strate the time effect and achieve a conclusive trial result .
In this report we describe the results of a randomized
double-blind trial of domiciliary versus hospital thromboly-
sis carried out in the Grampian region of Scotland. To
maximize time saving, participation in the trial was confined
to practices located z26 km (mean 58) from the hospital to
which patients were referee":', . in the United Kingdom, and in
northeast Scotland partccularly, there is a strong tradition of
primary medical care by general practitioners, and house
calls are the norm. Almos•+ all culls from patients with chest
pain are directed to general practitioners. The prehospital
phase of the trial was conducted in this setting . We therefore
believe that the hospital delays were not greatly changed by
the conduct of the trial, and the time saved is much greater
than that reported in other studies of prehospital thrombol-
ysis where prehospital treatment was provided or directed
by hospital staff members. Because of this and the rural
location of the practices, the overall time saved is substan-
tial, maximizing the chances of demonstrating the time
effect .
A full report of the trial giving mortality results up to 3
months (15) has been published elsewhere . In this report the
trial is described briefly, and mortality up to 1 year is
reported .
Methods
One hundred general practitioners from 29 practices
agreed to participate in the trial . The practices were located
in country towns and villages 16 to 62 road miles (mean
58 km) from Aberdeen, where all patients were admitted to
the hospital .
Inclusion and exclusion criteria . Entry into the trial was
based on strong clinical suspicion of acute myocardial in-
farction by the general practitioner . Symptoms characteris-
tic of myocardial infarction had to have been present for
?20 min but s4 h. General practitioners were required to
record an electrocardiogram (ECG) but not to report it for
trial entry .
Exclusion criteria were thrombolytic therapy within the
previous 6 months ; surgery or major trauma within the
previous 10 days ; active gastrointestinal bleeding or a his-
tory of any other internal bleeding within the previous 6
months; cerebrovascular accident or neurosurgical proce-
dure within the previous 2 months or a known intracranial
neoplasm or aneurysm; history of thrombocytopenia or
hemorrhagic diathesis or anticoagulant treatment ; risk of
pregnancy or heavy vaginal bleeding ; diabetic proliferative
retinopathy ; blood pressure X2001120 mm Hg ; recent resus-
citation with chest compression ; previous entry into the
trial, and participation in another clinical trial .
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The study was approved by the joint ethical committee of
the Grampian Health Board and the University of Aberdeen .
Conduct of the study . Practitioners were provided with
trial packs consisting of paired ampoules of anistreplase
(30 U) and matching piaccbo . The ampoules were randomly
labeled "home injection" and "hospital injection" by the
supplying pharmaceutical company. When a doctor had a
patient eligible for the trial, he or she gave the home injection
intravenously for 5 min and noted the time . The hospital
injection was then sent with the patient to the hospital in
Aberdeen. After assessment by the admitting physician, the
hospital injection was given and the time noted . Only if there
were contraindications or a proved alternative diagnosis was
the hospital injection withheld . All patients were followed up
for I year.
Statistical considerations . The purpose of the trial was
primarily to assess the feasibility and safety of prehospital
'hrombolysis by general practitioners . Measurement of effi-
cacy was a secondary aim. The target number of patients to
ke recruited during 2 years was 500, which would have given
80% power to confirm or exclude an absolute difference of
8% in mortality rate . Because a difference of that magnitude
was not expected, surrogate end points were used to assess
efficacy . Toward the end of 1990, when the trial had been
running for 2 years, only 200 patients had been recruited .
The decision was taken to terminate the trial at the end of
1991 regardless of the number of patients recruited by that
time. It was considered that sufficient information on feasi-
bility and safety would have been available by then .
All analyses are by "intention to treat ." Patients receiv-
ing anistreplase at home and intended to receive placebo in
the hospital are referred to as the home group, and those
receiving placebo at home and intended to receive anis-
treplase in the hospital are referred to as the hospital group .
Results
Baseline comparison of groups. Of 311 patients recruited,
163 were allotted to receive anistreplase at home and 148 to
receive it in the hospital (Table 1) . The two groups were well
matched for age, gender, clinical condition, ECG abnormal-
ity and history of angina, but there were significantly more
patients with a previous infarction in the home group .
Time savings. The median times of injection of active
anistreplase at home and in the hospital were 101 min (range
25 to 360) and 240 min (range 80 to 540), respectively (Fig . 1) .
The median time difference between home and hospital
injections was 130 min (range 40 to 370) .
In 22 (13%) of 163 patients allotted to anistreplase therapy
at home, the drug was given within I h of the onset of
symptoms, and in 104 (64%) of 163 patients it was given
within 2 h. Only I (1%) of 148 patients allotted to receive
anistreplase in the hospital received it within 2 h and none
within I h .
No record was kept of the time of arrival of the ambu-
lance at the hospital. However, the average speed of the
JACC Vol. 23, No
. I
January 1994:1-5
Table 1 . Baseline Comparison of Patients
Unless otherwise indicated, data are presented as number in group (%) .
BP = blood pressure ; ECU = electrocardiography ; M! = myocardial infarc-
tion.
ambulance was estimated at 46 mph, giving an approximate
journey time of 47 min . Subtracting the journey time from
the mean interval between home and hospital injections of
134 min gives a delay of -87 min ; most of this represents
delay in the hospital .
Mortality. Figure 2 shows the 1-year survival curves for
the home and hospital groups . In the home group there were
three, eight, and six deaths from all causes occurring,
respectively, in the prehospital period, in the hospital and in
the 1st year of follow-up . The corresponding figures for the
hospital group were 5, 12 and 15 deaths .
By the end of I year after trial entry, 17 (10 .4%) of 163
patients given anistreplase at home had died compared with
32 (21 .6%) of 148 patients allotted to receive anistreplase in
the hospital (relative reduction 52%, 95% confidence interval
14% to 89%, p = 0 .007) .
Figure 1 . Graphs showing the cumulative percent of patients in the
home and hospital groups who had received anistreplase at various
times after the onset of symptoms .
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Figure 2 . One-year survival curves for the home and hospital groups
in the Grampian Region Early Anistreplase Trial . CI = confidence
interval .
Discussion
The Grampian Region Early Anistreplase Trial (GREAT)
is the first to report a significai -it reduction in mortality with
prehospital compared with hospital administration of throm-
bolytic therapy. In this trial, general practitioners provided a
high standard of prehospital coronary care (15) . They re-
sponded promptly, were proficient in resuscitation and were
accurate in their clinical assessment . They relieved pain with
opiates, administered other drugs as necessary and initiated
thrombolytic therapy . Anistreplase was used because it is
given intravenously by bolus injection rather than by slow
intravenous infusion . The convenience of use of anistreplase
makes it the thrombolytic agent of choice for domiciliary
use. Compared with hospital administration, domiciliary
thrombolysis resulted in a time saving >2 h .
Time saved. Approximately two thirds of the time saved
by domiciliary thrombolysis in GREAT represented hospital
delay, estimated at a mean of 87 min. This compares well
with audited delays of 88 min in six British hospitals (14) and
84 min in eight American hospitals (13), none of which were
engaged in prehospital studies . These times contrast with
much shorter hospital delays reported by other studies of
prehospital thrombolysis . In the Myocardial Infarction Tri-
age and Intervention Project (MITI) (16), the overall time
saved was 33 min, of which hospital delay accounted for
only a few minutes. Assessment of the patient in the com-
munity by the paramedical staff of the mobile coronary care
unit greatly expedited the administration of therapy once the
patient arrived in the hospital
. A similar phenomenon was
reported by the European Myocardial Infarction Project
(EMIP) (17), where the overall time saved was 55 min, of
which 15 min was accounted for by the hospital delay (17). In
some centers the same hospital-based staff that provided the
prehospital care and assessment also gave the hospital
treatment, with the consequence that delay was negligible
once the hospital had been reached .
In tie Reperfusion in Acute Infarction Rotterdam study
Home Group
Hospital
Croup
(n = 163) (n = 148)
Age (yrl (mean : range) 64 ; 41-85 63 ; 32-93
Male patients 110(67) 106(72)
Previous MI 45 (28) 22 (15)
Previous angina 80 (49) 69(47)
Pulse rate (beatsfinin) (mean ; range) 78 ; 40-190 77 ; 35-180
Systolic BP (min Hg) (mean ; range) 134,90-200 135 -, 60-210
Diastolic BP (mm Hg) (mean ; range) 91 ; 40-112 82 ; 0-130
ECU
ST segment elevation 78(48) 81(55)
Nonspecific 59 (36) 45(30)
Normal 12(7) 14(10)
Not available 14 (9) 8 (5)
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(18),
the overall time saved was 47 min, of which 28 min was
the hospital delay. The investigators acknowledge that the
hospital delays in other hospitals in Rotterdam are consid-
erably longer.
Thus, in these three prehospital studies, the conduct of
the study led to a marked shortening of the time to throm-
bolysis in the hospital . Although this may have improved the
outcome for all patients participating in the studies, it made
it more difficult to demonstrate the benefit of earlier throm-
bolytic therapy .
The conduct of GREAT, perhaps because hospital per-
sonnel were not involved in the prehospital phase, appears
not to have resulted in any major change in practice in the
participating hospitals. Consequently, the time savings dem-
onstrated in GREAT are representative of those that are
likely to be made if domiciliary thrombolysis becomes es-
tablished practice and delays in hospital are not reduced .
Benefits of early thrombolysis. In GREAT, the median
times of administration of anistreplase at home and in the
hospital were 101 and 240 min, respectively, after symptom
onset, a median time saving of 130 min. Throughout the I st
year after trial entry, the mortality rate in patients receiving
thrombolytic therapy at home was approximately half that of
patients receiving it in the hospital . In addition, patients in
the home group had fewer Q wave infarcts and better left
ventricular function (15). These benefits were greatest in
those who received therapy within 2 h of symptom onset,
indicating that the time effect is not linear . Efficacy appears
to be greatly increased when thrombolytic therapy is given
within 2 h of symptom onset. A stepup in efficacy of
thrombolytic therapy when it is given within 2 h, especially
pronounced within I h, has been reported by others (19-21) .
Other randomized trials of prehospital thrombolysis. The
results from GREAT are fully in accord with those of other
randomized trials of prehospital thrombolysis . In EMIP, the
largest of these, the median times of administration of
thrombolytic therapy in the prehospital and hospital periods
were 130 and 190 min, respectively, after symptom onset ;
there was a 13% relative reduction in all-cause mortality with
prehospital thrombolysis (p = 0 .08) (17) . However, in the
subset of patients with a home to hospital delay >90 min,
mortality was almost halved, as in GREAT.
In MITI, the time difference between prehospital and
in-hospital thromboiysis was only 33 min, and nearly all
patients received therapy within 3 h of symptom onset .
There was no significant difference in left ventricular ejec-
tion fraction or myocardial infarct size between the two
groups (16) .
In a study from Tel Aviv, 118 patients were allotted
recombinant tissue-type plasminogen activator in the pre-
hospital or in-hospital period, which they received at 94 and
137 min, respectively, after the onset of symptoms, a mean
time difference of 43 min
. There were no significant differ-
ences in myocardial necrosis, coronary artery patency, left
ventricular ejection fraction, hospital stay or mortality
(22) .
Seventy-eight patients in Hamburg were allotted to re-
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ceive urokinase at a mean time after symptom onset of 85
and 137 min in the pre-hospital and in-hospital periods,
respectively (difference 52 min) . There were no significant
differences in coronary artery patency, global or regional left
ventricular function or peak creatine kinase (23) .
In a feasibility and safety study in Paris, IGO patients were
randomized to receive APSAC at home or in the hospital,
which was given at median times of 131 and 180 min,
respectively, after symptom onset (24) .
In all of these randomized studies of prehospital throm-
bolysis, there was considerable overlap in the times of
prehospital and in-hospital injections, and a high proportion
of patients in the hospital groups, as well as most of the
patients in the prehospital groups, received thrombolytic
therapy within 2 h of symptom onset, at a time of enhanced
efficacy . The shortened home to hospital delays brought
about by the conduct of these trials militated against dem-
onstrating the benefit of prehospital thrombolysis . In addi-
tion, several trials were too small to produce conclusive
evidence of benefit. Meta-analysis of all of the randomized
trials of prehospital thrombolysis has shown a 17% (p =
0.03) relative reduction in mortality with prehospital admin-
istration (17) .
Conclusions. In GREAT, the time to thrombolysis was
shortened by >2 h by administration of thrombolytic therapy
in the patient's home by general practitioners . Prehospital
thrombolysis resulted in a halving of mortality from acute
myocardial infarction . The clinical importance of giving
thrombolytic therapy at the first opportunity niay be greater
than is generally appreciated .
Appendix
Study Participants
General practitioners : The Grampian Region Early Anistreplase Trial
(GREAT) R. Gatenby, K. Lyons, Aberchirder ; T . Stewart, J. Taylor, J . Scott,
Aboyne; G. Payne, J . Reid, Afford; D. Glass, Ballater; D. Carroll, A.
McLean, 0. Mennie. F. Mair, D. Barela; , M . McCrone, K. Morton,
Banchory; N . Kennedy, J . Anderson, D . Inns, D . Scott, C . Gut_h_rie, Banff-,
H. Dawson, Braemar ; J . Kinnon, B. Murray, Crimond; K. Fraser, Cumin-
estown ; W. Morrison . C . Burgess, A . Donaldson, M . Pucci, 1 . Simpson, D.
McKetcher, I . Mackay, R. Bell, Ellon ; R . Bichan, G . Gordon, A . Hayworth,
R. Massie, A. Wisley, V. Tosh, W. Steele, E . Wilson, R . Logan, H . Nicol, 1 .
McLean, Fraserburgh ; A . Taylor, S . Robertson, R . Wallace, D. Connell,
Fyvie-Oldmeldrum ; J. Rae, Gardenstown; G . Ferguson, J . Sandeman, Hat-
ton ; E. Cosgrove, G . Shirreffs, D. Easton, A. Sinclair, G . Carter, Huntly ; M .
Kay, H . Mackie, G. Momce, (nsch ; V . Johnston, A . Fisken, J . Beattie, J .
Black, J . MacDonald, G . Gill, I . Cruickshank, D. Hood, S. Harkness, D .
Smylic, Inverurie ; M . Morrison. J. Harrington, G . Herd, R. Hutchison, J .
Thomason, Keith ; D . Hawson, G . Young, P. Green, N . Mack, Kemnay ; I .
Brooker, A. Barbour, Macduf; J . Miller . A. Gauld, T. Goodbrarsl, R .
McInnes, D . Nicol, Mintfaw ; A. Robertson, D . McLeman, S . Crockett, New
Deer, I . Taylor, Portsoy ; A. Morgan, G . McIntosh, A. Stewart, J. Herd, J .
Smith, A . MacCuish, Stonehaven ; A . de Laat, A. Sneddon, Strathdon ; D.
Crowley, Tomintout ; A . Duthie, R . Fraser, A. Smith, R. Liddell, Turrif.
Cardiologists and physicians : J . Bevan, P. Bewsher, P. Brunt, N. Ben-
jamin, G . Catto, N . Edward, R . Himsworth, A. Jeffers, K. Jennings, A .
Johnston, A. Kenmure, A . McLeod, A . Mowat, L . Murchison, D. Pearson, J .
Petrie, D . Power, J . Rawles, T . Sinclair, C . Smith, S . Walton . J. Webster, M .
Williams.
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Coordinators : J . Light, M . Wait.
Technician : J . McKnight
.
SmithKline Beecham : M . Simpson . F . Cree, M . Wellwood .
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